That's the key word: lost. Nothing's been lost - neither Eli Lilly nor their shareholders have lost any money (unless they sold their stock, at which point they aren't shareholders). The price of their stock dipped, and is rising back up.
At worst, Eli Lilly would have had slightly higher interest rates on their next round of debt funding.
